Second Generation Patents in Pharmaceutical Innovation
The development of new medications and improvements thereof are crucial to ensure continued gains in health. The development process is long and costly, and mainly to produce the information to meet high regulatory requirements. In contrast, imitation involves negligible costs and much reduced risks...
Saved in:
Main Author: | Ahn, Hyewon (auth) |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Nomos Verlagsgesellschaft mbH & Co. KG
2014
|
Series: | Munich Intellectual Property Law Center - MIPLC
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patentability of Chemical Selection Inventions: The Olanzapine and Escitalopram Decisions
by: Ahn, Hyewon
Published: (2011) -
Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?
by: Donghi, Monica
Published: (2014) -
The Role of the Patent System in Stimulating Innovation and Technology Transfer for Climate Change Including Aspects of Licensing and Competition Law
by: Kim, Hee-Eun
Published: (2011) -
Patenting Proteomics Patentability and Scope of Protection of Three-Dimensional Protein Structure Claims under German, European and US law
by: Schuster, Martina
Published: (2010) -
Patentability Requirements for Nanotechnological Inventions An Approach from the European Patent Convention Perspective
by: Cisneros, Mario
Published: (2009)